Shah et al Lifetime 65-year-old patient with SBRT had mean Wedge resection, Markov model Payer SBRT was the cost-effective strategy for marginally () medically operable cost and and lobectomy developed to operable patients. Lobectomy was most stage I NSCLC in USA. life had a mean cost compare the effective in clearly operable patients, Local recurrence rate for expectancy of and of SBRT obtained from a $42,094/8.03 - life SBRT with wedge 3-year study of $40,107/8.21 expectancy of resection and potentially operable $51,487/7.93 and lobectomy for clearly patients in the $49,093/8.89. and marginally Netherlands operable patients Lester-Coll 10 years, Study undertaken at the 10 year cost of Patients Markov model to Payer The ICER for SBRT over systemic therapy was et al () using 3% Department of SBRT was underwent SBRT study a hypothetical $95,879/quality adjusted life month (QALM) for colon discount Therapeutic Radiology, $1,286,700 or systemic cohort of patients with cancer rate Yale University School therapy (FOLFIRI oligometastatic colon of Medicine, and so or Ipilimumab). cancer or USA perspective FOLFIRI and had with 1–3 pulmonary assumed. Cohort entry a 10-year cost of metastases. age not specified, $1,733,293 although tracked for 10 years. Lanni et al 6 years 86 patients with Stage I $13,639 for $10,616 Cost calculated using Payer SBRT was less costly when compared to standard () (Tl-2 N0) NSCLC in the EBRT 2010 Medicare fractionated EBRT, It was also found to have for SBRT USA hospital-based superior local control and overall survival ambulatory payment and hospital-based physician fee screen reimbursement rates.
effective Shah et al () Lifetime 65-year-old patient with medically operable stage I NSCLC in USA. Local recurrence rate for SBRT obtained from a 3-year study of potentially operable patients in the Netherlands SBRT had mean cost and life expectancy of $42,094/8.03 - $40,107/8.21 Wedge resection, and lobectomy had a mean cost and life expectancy of $51,487/7.93 and $49,093/8.89. Markov model developed to compare the of SBRT with wedge resection and lobectomy for clearly and marginally operable patients Payer SBRT was the cost-effective strategy for marginally operable patients. Lobectomy was most in clearly operable patients, Lester-Coll et al () 10 years, using 3% discount rate Study undertaken at the Department of Therapeutic Radiology, Yale University School of Medicine, and so USA perspective assumed. Cohort entry age not specified, although tracked for 10 years. 10 year cost of SBRT was $1,286,700 Patients underwent SBRT or systemic therapy (FOLFIRI or Ipilimumab). FOLFIRI and had a 10-year cost of $1,733,293 Markov model to study a hypothetical cohort of patients with oligometastatic colon cancer or with 1–3 pulmonary metastases. Payer The ICER for SBRT over systemic therapy was $95,879/quality adjusted life month (QALM) for colon cancer Lanni et al () 6 years 86 patients with Stage I (Tl-2 N0) NSCLC in the USA $13,639 for EBRT $10,616 for SBRT Cost calculated using 2010 Medicare hospital-based ambulatory payment and hospital-based physician fee screen reimbursement rates. Payer SBRT was less costly when compared to standard fractionated EBRT, It was also found to have superior local control and overall survival